Literature DB >> 3941594

Preference conditioning produced by opioid active and inactive isomers of levorphanol and morphine in rat.

R F Mucha, A Herz.   

Abstract

Using taste and place preference conditioning, the present study examined the motivational properties produced in adult rats by systemic administration of (-) and (+) morphine, levorphanol, and dextrorphan. Conditioned place preference was stereospecific; it was only produced by the opioid receptor active isomers, levorphanol and (-) morphine. Similarly, a conditioned taste preference produced by a low dose of morphine was only seen with the active isomer. Conditioned taste aversion, however, was produced in a comparable dose range by both the active and the inactive isomers. In addition injections of inactive isomers also produced tolerance to the taste aversion produced by (-) morphine. Therefore, administration of both opioid active and inactive isomers of opioid agonists are unconditioned stimuli for the production of preference behaviors. In addition, it was concluded that the appetitive reinforcing properties of these drugs, seen as taste and place preferences, appear to require activation of specific opioid receptors, whereas the aversive effects, seen as taste aversion may also involve other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941594     DOI: 10.1016/0024-3205(86)90309-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Drug-motivated behavior in rats with lesions of the thalamic orosensory area.

Authors:  Jennifer E Nyland; Danielle N Alexander; Patricia S Grigson
Journal:  Behav Neurosci       Date:  2015-12-14       Impact factor: 1.912

2.  Reward Comparison: The Achilles' heel and hope for addiction.

Authors:  Patricia Sue Grigson
Journal:  Drug Discov Today Dis Models       Date:  2008

3.  Conditioning of morphine-induced taste aversion and analgesia.

Authors:  J S Miller; K S Kelly; J L Neisewander; D F McCoy; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor.

Authors:  Mark A Smith; Kara A Chisholm; Paul A Bryant; Jennifer L Greene; Jacob M McClean; William W Stoops; David L Yancey
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 6.  The state of the reward comparison hypothesis: theoretical comment on Huang and Hsiao (2008).

Authors:  Patricia Sue Grigson
Journal:  Behav Neurosci       Date:  2008-12       Impact factor: 1.912

7.  Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens.

Authors:  Eagle Y-K Huang; Te-Chen Liu; Pao-Luh Tao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-15       Impact factor: 3.000

8.  Smoking stimuli from the terminal phase of cigarette consumption may not be cues for smoking in healthy smokers.

Authors:  Ronald F Mucha; Paul Pauli; Markus Weber; Markus Winkler
Journal:  Psychopharmacology (Berl)       Date:  2008-08-15       Impact factor: 4.530

9.  (+)-Morphine attenuates the (-)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated dopamine increase in the posterior nucleus accumbens of the rat.

Authors:  Maia Terashvili; Hsiang-En Wu; Emma T Schwasinger; Kuei-Chun Hung; Jau-Shyong Hong; Leon F Tseng
Journal:  Eur J Pharmacol       Date:  2008-03-29       Impact factor: 4.432

Review 10.  Classical conditioning and pain: conditioned analgesia and hyperalgesia.

Authors:  Gonzalo Miguez; Mario A Laborda; Ralph R Miller
Journal:  Acta Psychol (Amst)       Date:  2013-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.